More pharmaceutical companies are working to understand how real world evidence (RWE) can strengthen their submission packages and identifying opportunities to do this across their portfolios. Join Nathalie Horowicz-Mehler, Senior Principal and Practice Lead of the Real World Evidence (RWE) team at IQVIA as she shares how RWE can be utilized to enhance regulatory submissions through three key takeaways:
• Improved understanding of global receptivity to RWE in Regulatory Submission including FDA, EMA, and Japan
• Understand how to identify an opportunity for RWE to inform submission package for your product or portfolio
• Use cases of real-world evidence in Regulatory Submission for effectiveness, especially for label expansions
Event is open to: HBA Members and Nonmembers. Register here by December 1st.
